Disease relevance of Perfuoro-n-pentane

• We investigated the ability of dodecafluoropentane (DDFP) to sensitize the moderately radiation-resistant Morris 7777 hepatoma based on our previous inability to modify the radiation response of this tumor [1].
• Protocol 2 assessed the effects of repeated injections of dodecafluoropentane (0.5 ml/kg body weight, four doses 30 min apart or eight doses 10 min apart) on myocardial blood flow and hemodynamic variables [2].
• Peripheral intravenous myocardial contrast echocardiography using a 2% dodecafluoropentane emulsion: identification of myocardial risk area and infarct size in the canine model of ischemia [2].
• However, experimental limitations (e.g., toxicity of 2,3-dichlorooctafluorobutane, and hypoxia from perfluoropentane) confound interpretation of these latter results [3].
• Exposure at room temperature, which was less than the 29 degrees C boiling point of perfluoropentane, eliminated the enhancement of the hemolysis effect relative to the blank [4].

High impact information on Perfuoro-n-pentane

• Flow dynamics of QW7437, a new dodecafluoropentane ultrasound contrast agent, in the microcirculation: microvascular mechanisms for persistent tissue echo enhancement [5].
• METHODS: Interparticulate forces of salbutamol sulphate (SS), budesonide (BUD) and formoterol fumarate dihydrate (FFD) were investigated by in situ atomic force microscopy (AFM) in a model propellant 2H, 3H perfluoropentane (HPFP) [6].
• At 0.1 predicted MAC, a second nonimmobilizer, perfluoropentane, tended (P = 0.05) to increase (11% +/- 9%) population spike amplitude, decreased population spike latency 8% +/- 2%, and tended (P = 0.06) to increase excitatory postsynaptic potentials (9% +/- 8%) [7].
• Pharmacokinetics do not explain the absence of an anesthetic effect of perfluoropropane or perfluoropentane [8].
• The forces of interaction between inhalable formoterol fumarate dihydrate particles, and the various components of a pressurised Metered Dose Inhaler (pMDI) (e.g. aluminium container, other drug particles and stabilising excipients) were investigated in isolation and combination in the model propellant 2H, 3H perfluoropentane (HPFP) [9].

Biological context of Perfuoro-n-pentane

• Extrapolation from these experiments indicates that less than 1 ml of DDFP, in emulsion-form, could provide for the resting oxygen consumption of an adult person [10].

Anatomical context of Perfuoro-n-pentane

• Doppler sonographic evaluation of the portal vein: effects of intravenous dodecafluoropentane [11].
• Dodecafluoropentane produced enhanced backscatter in the carotid artery in all patients, and for a mean duration longer than that reported for other agents [12].
• The purpose of this study was to characterize the time-course of the opacification of the heart cavities and myocardium with a new long-lasting second-generation, phospholipid-based echo contrast agent containing perfluoropentane (BY963-C5F12), and to compare its contrast potency with that of air-filled phospholipid monolayer (BY963-air) [13].
• To assess the efficacy in carotid diagnosis of an investigational dodecafluoropentane ultrasonic contrast enhancing agent, we compared B-mode, color flow, and duplex Doppler findings in 16 patients with common carotid artery bifurcation disease after dodecafluoropentane and saline injections [12].

Associations of Perfuoro-n-pentane with other chemical compounds

• The time course of in vitro stability of BY963 agitated with the different gases measured by absorbance of light (500 nm) showed a retarded decay for perfluoropentane, a rapid decrease for air, isopentane, trichlortrifluoroethane, and argon, and a very rapid decrease using isoflurane [14].

Analytical, diagnostic and therapeutic context of Perfuoro-n-pentane

• OBJECTIVES: We examined the effectiveness of the microbubbles of an echo contrast agent, dodecafluoropentane (DDFP) emulsion, to enhance low frequency ultrasound clot disruption in vitro and in vivo [15].
• Myocardial contrast echocardiography using intravenous dodecafluoropentane accurately defined myocardial area at risk and infarct size [2].
• Dodecafluoropentane offers the potential for reliable, noninvasive assessment of reperfusion after therapeutic interventions [2].
• OBJECTIVES: The purpose of this study was to test the hypothesis that a subgroup of QW7437 microbubbles, dodecafluoropentane-based ultrasound contrast microspheres, resides for prolonged periods in the microvasculature [5].
• Dodecafluoropentane produced enhanced backscatter in all patients for 4 to 20 min (mean, 8.4+/-4.74 min) after intravenous injection [12].

References